Serum concentration of L-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP

European Journal of Haematology

Volumn 84, Issue 4, 2010, Pages 304-309

  Yoshikawa, Takeshi ^a   Hara, Takeshi ^a   Tsurumi, Hisashi ^a   Goto, Naoe ^a   Hoshi, Masato ^a   Kitagawa, Junichi ^a   Kanemura, Nobuhiro ^a   Kasahara, Senji ^a   Ito, Hiroyasu ^a   Takemura, Masao ^a   Saito, Kuniaki ^b   Seishima, Mitsuru ^a   Takami, Tsuyoshi ^a   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Immunological tolerance; Indoleamine 2, 3 dioxygenase; L tryptophan catabolism; Prognostic factor

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; KYNURENINE; LACTATE DEHYDROGENASE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; AGE; AGED; ARTICLE; B CELL LYMPHOMA; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RATING SCALE; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; KYNURENINE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISOLONE; REMISSION INDUCTION; SURVIVAL RATE; VINCRISTINE;

EID: 77949456437     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01393.x     Document Type: Article

References (36)

1. Nicolaides C, Dimou S, Pavlidisa N. Prognostic factors in aggressive non-Hodgkin's lymphomas. Oncologist 1998;3:189-97.
2. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329: 987-94.
3. Hara T, Tsurumi H, Takemura M, Goto H, Yamada T, Sawada M, Takahashi T, Moriwaki H. Serum-soluble fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma. Am J Hematol 2000;64:257-61.
4. Goto H, Tsurumi H, Takemura M, et al. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index. J Cancer Res Clin Oncol 2005;131:73-9.
5. Goto N, Tsurumi H, Takemura M, et al. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma. Eur J Haematol 2006;77:217-25.
6. Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 1999;20:469-73.
7. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999;189:1363-72.
8. Murray HW, Szuro-Sudol A, Wellner D, Oca MJ, Granger AM, Libby DM, Rothermel CD, Rubin BY. Role of tryptophan degradation in respiratory burst-independent antimicrobial activity of gamma interferon-stimulated human macrophages. Infect Immun 1989;57:845-9.
9. Fujigaki S, Saito K, Sekikawa K, Tone S, Takikawa O, Fujii H, Wada H, Noma A, Seishima M. Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an IFN-gamma-independent mechanism. Eur J Immunol 2001;31:2313-8.
10. Fujigaki H, Saito K, Fujigaki S, Takemura M, Sudo K, Ishiguro H, Seishima M. The signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2,3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein kinase and nuclear factorkappaB pathways, and synergistic effect of several proinflammatory cytokines. J Biochem 2006;139:655-62.
11. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 2002;196:459-68.
12. Huang A, Fuchs D, Widner B, Glover C, Henderson DC, Allen-Mersh TG. Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer 2002;86:1691-6.
13. World Health Organization. Classification of Tumors, Pathology and Genetics Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001.
14. Fujigaki S, Saito K, Takemura M, Fujii H, Wada H, Noma A, Seishima M. Species differences in L-tryptophan-kynurenine pathway metabolism: quantification of anthranilic acid and its related enzymes. Arch Biochem Biophys 1998;358:329-35.
15. Takagi T, Oguro M. (2″-R)-4′-o-tetrahydropyranyladriamycin, a new anthracycline derivative; its effectiveness in lymphoid malignancies. Cancer Chemother Pharmacol 1987;20:151-4.
16. Miller AA, Salewski E. Prospects for pirarubicin. Med Pediatr Oncol 1994;22:261-8.
17. Tsurumi H, Yamada T, Sawada M, et al. Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study. J Cancer Res Clin Oncol 2004;130:107-13.
18. Hara T, Tsurumi H, Goto N, et al. Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma. J Cancer Res Clin Oncol 2010;136:65-70.
19. Tsurumi H, Hara T, Goto N, et al. A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma. Hematol Oncol 2007;25:107-14.
20. Sawada M, Tsurumi H, Yamada T, et al. A prospective study of P-IMVP-16?CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy. Eur J Haematol 2002;68:354-61.
21. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
22. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-61.
23. Giusti RM, Maloney EM, Hanchard B, Morgan OS, Steinberg SM, Wachter H, Williams E, Cranston B, Fuchs D, Manns A. Differential patterns of serum biomarkers of immune activation in human T-cell lymphotropic virus type I-associated myelopathy?tropical spastic paraparesis, and adult T-cell leukemia?lymphoma. Cancer Epidemiol Biomarkers Prev 1996;5:699- 704.
24. Hu B, Hissong BD, Carlin JM. Interleukin-1 enhances indoleamine 2,3-dioxygenase activity by increasing specific mRNA expression in human mononuclear phagocytes. J Interferon Cytokine Res 1995;15:617-24.
25. Hissong BD, Carlin JM. Potentiation of interferon-induced indoleamine 2,3-dioxygenase mRNA in human mononuclear phagocytes by lipopolysaccharide and interleukin-1. J Interferon Cytokine Res 1997;17:387-93.
26. Currier AR, Ziegler MH, Riley MM, Babcock TA, Telbis VP, Carlin JM. Tumor necrosis factor-alpha and lipopolysaccharide enhance interferon-induced antichlamydial indoleamine dioxygenase activity independently. J Interferon Cytokine Res 2000;20:369-76.
27. Babcock TA, Carlin JM. Transcriptional activation of indoleamine dioxygenase by interleukin 1 and tumor necrosis factor alpha in interferon-treated epithelial cells. Cytokine 2000;12:588-94.
28. Robinson CM, Shirey KA, Carlin JM. Synergistic transcriptional activation of indoleamine dioxygenase by IFN-gamma and tumor necrosis factor-alpha. J Interferon Cytokine Res 2003;23:413-21.
29. Chon SY, Hassanain HH, Pine R, Gupta SL. Involvement of two regulatory elements in interferon-gamma-regulated expression of human indoleamine 2,3-dioxygenase gene. J Interferon Cytokine Res 1995;15:517-26.
30. Chon SY, Hassanain HH, Gupta SL. Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferon-gamma- inducible expression of human indoleamine 2,3-dioxygenase gene. J Biol Chem 1996;271:17247-52.
31. Robinson CM, Hale PT, Carlin JM. The role of IFN-gamma and TNF-alpha-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase. J Interferon Cytokine Res 2005;25:20-30.
32. Zacharos ID, Efstathiou SP, Petreli E, Georgiou G, Tsioulos DI, Mastorantonakis SE, Christakopoulou I, Roussou PP. The prognostic significance of CA 125 in patients with non-Hodgkin's lymphoma. Eur J Haematol 2002;69:221-6.
33. Lazzarino M, Orlandi E, Klersy C, Astori C, Brusamolino E, Corso A, Bellio L, Gargantini L, Morra E, Bernasconi C. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: correlation with tumor parameters and disease activity. Cancer 1998;82:576-82.
34. Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K, Saito H, Hotta T. Mutations of p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 1997;337:529-34.
35. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
36. Niitsu N, Okabe-Kado J, Okamoto M, Takagi T, Yoshida T, Aoki S, Hirano M, Honma Y. Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma. Blood 2001;97:1202-10.